Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Mar:165:105473.
doi: 10.1016/j.phrs.2021.105473. Epub 2021 Jan 30.

Anticoagulant or antiplatelet use and severe COVID-19 disease: A propensity score-matched territory-wide study

Jiandong Zhou  1 , Sharen Lee  2 , Cosmos Liutao Guo  2 , Carlin Chang  3 , Tong Liu  4 , Keith Sai Kit Leung  5 , Abraham Ka Chung Wai  6 , Bernard Man Yung Cheung  7 , Gary Tse  8 , Qingpeng Zhang  9
Affiliations
Comment

Anticoagulant or antiplatelet use and severe COVID-19 disease: A propensity score-matched territory-wide study

Jiandong Zhou et al. Pharmacol Res. 2021 Mar.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Procedures of data processing.
Fig. 2
Fig. 2
Kaplan-Meier curve for the severe disease outcome in PCR-positive COVID-19 patients stratified by anticoagulant (AC)/ antiplatelet (AP) use after 1:2 propensity score matching.
Fig. 3
Fig. 3
Kaplan-Meier curve for the severe disease outcome in PCR-positive COVID-19 patients receiving antiviral or steroid therapy, stratified by anticoagulant (AC)/ antiplatelet (AP) use after 1:2 propensity score matching.
See this image and copyright information in PMC

Comment on

References

    1. Russo V., Di Maio M., Attena E., Silverio A., Scudiero F., Celentani D., Lodigiani C., Di Micco P. Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: a multicenter observational study. Pharmacol. Res. 2020;159 - PMC - PubMed
    1. Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemost. 2020;18(5):1094–1099. - PMC - PubMed
    1. Paranjpe I., Fuster V., Lala A., Russak A.J., Glicksberg B.S., Levin M.A., Charney A.W., Narula J., Fayad Z.A., Bagiella E., Zhao S., Nadkarni G.N. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients With COVID-19. J. Am. Coll. Cardiol. 2020;76(1):122–124. - PMC - PubMed
    1. Zhou J., Wang X., Lee S., Wu W.K.K., Cheung B.M.Y., Zhang Q., Tse G. Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score matched territory-wide study. Gut. 2020 - PubMed
    1. Li X., Guan B., Su T., Liu W., Chen M., Bin Waleed K., Guan X., Gary T., Zhu Z. Impact of cardiovascular disease and cardiac injury on in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis. Heart. 2020;106(15):1142–1147. - PMC - PubMed